@FierceBiotech: Progress seen in 'miracle' line of attack against genetic disorders. Report | Follow @FierceBiotech
@JohnCFierce: It's off to Paris tonight and some sitdowns with the Europeans next week. Still working, though, so keep the tweets and emails coming. Follow @JohnCFierce
> Shares of Pluristem Therapeutics ($PSTI) surged after the biotech reported that it has landed a $55 million deal with United Therapeutics to develop new drugs for pulmonary hypertension. Pluristem gets $7 million of that up front. Story
> Paul Grayson, the former CEO at Fate Therapeutics, is taking the helm at La Jolla, CA-based Anaphore. He's replacing Katherine S. Bowdish, Ph.D., a co-founder of Anaphore, who will continue to serve as a consultant. Anaphore release
> Concert Pharmaceuticals has achieved a $4 million milestone in its strategic alliance with GlaxoSmithKline for its HIV protease inhibitor development program. Concert release
> Science Applications International Corporation says it has won a follow-on contract with the U.S. Army Medical Research and Materiel Command to provide scientific and other support services to the Congressionally Directed Medical Research Programs. Report
@FiercePharma: Pharma marketers band together on social media. Report | Follow @FiercePharma
> Report: Lilly must buy company or be acquired. News
> J&J recalling 40K bottles of Risperdal. Article
> J&J scores win in Levaquin trial. Report
Biotech IT News
> Supercomputing poised for leading R&D role in personalized medicine. Editor's note
> PerkinElmer, others ride 'wave' of genomic data going to the cloud. Report
> AstraZeneca plans tech center in Russia, aims to use informatics to predict drug safety. Story
> Public funds costly for Aussie life sciences supercomputing plan? Article
> Knome automates analysis of NGS data, evolves in genomics field. Report
Medical Device News
> Minnesota students to evaluate Chinese med tech. Report
> Medtronic reports positive results with Valiant. Item
> Philips, ROSATOM ink nuclear medicine MOU. News
> Case against 3M opens in the U.K. Story
> Jan Medical nabs $3.15M in Series A. Article
And Finally...Investigators at the Mayo Clinic and their collaborators in the U.K. say they cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. Release